These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25903089)

  • 21. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
    Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
    Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
    J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands.
    Pötter R; Prott FJ; Micke O; Haverkamp U; Wagner W; Willich N
    Strahlenther Onkol; 1999 Jun; 175 Suppl 2():65-8. PubMed ID: 10394401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
    Hoover AC; Milhem MM; Anderson CM; Sun W; Smith BJ; Hoffman HT; Buatti JM
    Head Neck; 2015 May; 37(5):722-6. PubMed ID: 24596143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
    Argiris A; Ghebremichael M; Burtness B; Axelrod RS; Deconti RC; Forastiere AA
    Cancer; 2011 Aug; 117(15):3374-82. PubMed ID: 21246525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
    J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
    Scheid C; Reece D; Beksac M; Spencer A; Callander N; Sonneveld P; Kalimi G; Cai C; Shi M; Scott JW; Stewart AK
    Eur J Haematol; 2015 Oct; 95(4):316-24. PubMed ID: 25402977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
    Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
    Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
    Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
    Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
    Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study.
    Amit M; Binenbaum Y; Sharma K; Ramer N; Ramer I; Agbetoba A; Miles B; Yang X; Lei D; Bjøerndal K; Godballe C; Mücke T; Wolff KD; Fliss D; Eckardt AM; Copelli C; Sesenna E; Palmer F; Patel S; Gil Z
    Head Neck; 2014 Jul; 36(7):998-1004. PubMed ID: 23784851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
    Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
    Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review.
    Papaspyrou G; Hoch S; Rinaldo A; Rodrigo JP; Takes RP; van Herpen C; Werner JA; Ferlito A
    Head Neck; 2011 Jun; 33(6):905-11. PubMed ID: 20652885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
    Ross PJ; Teoh EM; A'hern RP; Rhys-Evans PH; Harrington KJ; Nutting CM; Gore ME
    Clin Oncol (R Coll Radiol); 2009 May; 21(4):311-4. PubMed ID: 19201585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
    Schäfer N; Gielen GH; Kebir S; Wieland A; Till A; Mack F; Schaub C; Tzaridis T; Reinartz R; Niessen M; Fimmers R; Simon M; Coch C; Fuhrmann C; Herrlinger U; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1581-9. PubMed ID: 27100354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective study of 18 cases of adenoid cystic cancer at a tertiary care centre in Delhi.
    Sharma K; Rathi AK; Khurana N; Mukherji A; Kumar V; Singh K; Bahadur AK
    Indian J Cancer; 2010; 47(4):424-9. PubMed ID: 21131757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
    Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
    Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of adenoid cystic carcinoma in nova scotia: 30-year population-based epidemiologic study.
    Bonaparte JP; Hart R; Trites J; Taylor MS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):642-8. PubMed ID: 19128670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.